A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.
about
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsGenotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*DGenome-wide pharmacogenomic analysis of response to treatment with antipsychotics.The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE studyReplication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trialGenome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Clinical predictors of therapeutic response to antipsychotics in schizophreniaEvidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicineGenome-wide association study of antipsychotic-induced QTc interval prolongation.Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia.Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PETTargeted pharmacogenetic analysis of antipsychotic response in the CATIE study.Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood.Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatmentBasal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset.An integrative functional genomics approach for discovering biomarkers in schizophrenia.A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine.Pharmacogenetics of second-generation antipsychotics.A genomewide association study of citalopram response in major depressive disorder-a psychometric approach.Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.
P2860
Q24630309-D5B0E4DB-2482-4C06-86FC-4D0DD68E9C60Q28486019-6BBE4EF3-592E-43AF-A1F9-A88C645D1102Q33926334-59B73020-F639-47B5-8EFD-631911800DDEQ33929926-875EE94F-7058-4E50-A66C-8ACDAE7B96A4Q34078643-C6D99CDD-8E9E-4696-84A2-ADC4CA5DDF34Q34155219-CB43A7CF-82F8-4248-B35C-87A05B6F7975Q34229109-E99C5B6E-1C41-4E3D-9B96-AC75A9C173C7Q34644655-252C42E8-7FD0-4839-AA8B-AD78401D44B2Q34661875-569255D0-B10F-4AAC-8EA3-B804DACB6707Q35109168-E2D1CACE-259A-474D-8C11-F7757BB9F21CQ35200854-DD641BAF-E183-4A50-BF51-0601BF4FE205Q35375788-860C84C0-59A1-4153-A7E2-723B17489920Q36073692-588EB04D-64BF-48F6-90CD-E471D902C0ABQ36135959-998724FA-0F89-4751-96FE-51CD7C8EBCF6Q36302841-9A423BCF-7AF9-4142-9DE4-77A94D385C3BQ36449077-9A65CDC7-4EC7-4E98-9E23-93477BB8AB59Q36456196-A120BC7C-2EE2-46E7-882B-CC86D08007C5Q36604310-70D73EE0-5500-4C68-AAB2-587844234CD9Q37353278-3EEA8AEB-9679-4BB1-B7DA-60492E35A3DCQ37441628-6E9A720C-96C3-4B40-AFE8-14DD924F6F5CQ37581282-21BF70B7-4D35-46C1-A1D8-F622FD33C27CQ37627386-73CC9FAA-BDA2-4A1A-AF56-192CEC29C6C3Q37706450-EEA06BF0-C1B8-4A29-A729-1C12D889B05DQ37966594-F21106B0-54D6-4337-9262-8F59E31A9A02Q37998840-D2785831-3800-4E2E-B1B9-49C9DCFB04E8Q38217628-2F538E59-89C4-47BB-8316-052BD45DA063Q42464234-A7437428-889F-4E89-82FD-D0B96946CCC1Q43474705-9A1AF7CE-F945-4B7A-BF09-2415AF723215
P2860
A systematic method for estimating individual responses to treatment with antipsychotics in CATIE.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic method for estima ...... with antipsychotics in CATIE.
@en
A systematic method for estima ...... with antipsychotics in CATIE.
@nl
type
label
A systematic method for estima ...... with antipsychotics in CATIE.
@en
A systematic method for estima ...... with antipsychotics in CATIE.
@nl
prefLabel
A systematic method for estima ...... with antipsychotics in CATIE.
@en
A systematic method for estima ...... with antipsychotics in CATIE.
@nl
P2093
P2860
P1476
A systematic method for estima ...... t with antipsychotics in CATIE
@en
P2093
Daniel E Adkins
Edwin J C G van den Oord
Patrick F Sullivan
P2860
P356
10.1016/J.SCHRES.2008.09.009
P407
P577
2008-10-18T00:00:00Z